Rapid Initiation of Antiretroviral Therapy to Promote Early HIV/AIDS Treatment in South Africa (RapIT Study) (RapIT)

January 3, 2019 updated by: Sydney Rosen, Boston University

One of the most serious challenges facing antiretroviral therapy (ART) programs for HIV/AIDS in resource-constrained settings is the failure of ART-eligible patients to complete the steps required to initiate treatment. The high rate of loss to care of patients who are treatment-eligible at HIV diagnosis may be due in part to the large number of steps required between receiving an HIV diagnosis and obtaining the first dose of antiretrovirals (ARVs). In South Africa, these steps usually require approximately four clinic visits over a period of 2-8 weeks before a patient can start treatment. One strategy proposed for reducing losses among those eligible for ART is to simplify and condense the steps required for starting treatment. This is now possible because new, point-of-care (POC) tests for CD4 counts and tuberculosis (TB) diagnosis are available. These technologies can be combined with changes to clinic schedules to allow all steps required for ART initiation under South African guidelines (lab tests, physical exam, education) to take place on the day the patient presents for an HIV test.

This study is a randomized strategy evaluation of the feasibility, effectiveness, and cost-effectiveness of rapid ART initiation. Outpatient, non-pregnant, HIV-positive adults who come to a South African clinic for an HIV test, consent to study participation, and are eligible for ART will be randomized 1:1 to rapid ART initiation or to standard care. Those who are assigned to rapid ART initiation will have the possibility of receiving their first dose of ARVs as early as the same day, while those who are assigned to standard care will follow the clinic's usual procedures for starting ART. Rapid ART initiation for HIV-positive pregnant women, which has recently become the standard of care in South Africa, will also be assessed in a programmatic evaluation conducted alongside the randomized evaluation, with a retrospective comparison group. The primary study outcome for non-pregnant adults will be remaining alive, in care and virally suppressed 10 months after having a positive HIV test at the study site or making a first HIV-related visit. The primary study outcome for pregnant women will be adherence to ART until delivery. The cost effectiveness of the rapid initiation strategy will be assessed as the cost per patient achieving the primary outcome for each population.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

531

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Gauteng
      • Johannesburg, Gauteng, South Africa, 2092
        • Thuthukani Primary Health Clinic
      • Johannesburg, Gauteng, South Africa
        • Themba Lethu Clinic, Helen Joseph Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adult patients (>18 years)
  • Tested HIV-positive at study site's outpatient testing service or antenatal clinic on day of study enrollment or previously tested HIV-positive but making first visit to study site for HIV-related care or antenatal care for the current pregnancy
  • Eligible for antiretroviral therapy under prevailing South African guidelines

Exclusion Criteria:

  • Currently or previously on ART (three-drug combination; previous PMTCT regimen exposure for an earlier pregnancy is not an exclusion criterion)
  • Stated intention to seek further HIV or antenatal care at another site, not at the study site
  • Not physically or emotionally able to participate in the study, in the opinion of the investigators
  • Not willing or able to provide written informed consent to participate in the study
  • Previously screened for the same study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Standard group, non-pregnant adults
Comparison group (prospective enrollment)
No Intervention: Standard group, pregnant women
Comparison group (retrospective record review)
Experimental: Rapid group, non-pregnant adults
Rapid ART initiation
Subjects offered the intervention who are eligible for antiretroviral therapy under South African guidelines will be offered the opportunity to initiate ART immediately, if possible on the same day as testing positive for HIV. Rapid testing technologies and an accelerated schedule will be used to allow all steps required prior to initiating ART to take place in approximately a half-day period.
Experimental: Rapid group, pregnant women
Rapid ART initiation
Subjects offered the intervention who are eligible for antiretroviral therapy under South African guidelines will be offered the opportunity to initiate ART immediately, if possible on the same day as testing positive for HIV. Rapid testing technologies and an accelerated schedule will be used to allow all steps required prior to initiating ART to take place in approximately a half-day period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion non-pregnant subjects virally suppressed at routine six-month viral load
Time Frame: 10 months after study enrollment
The primary outcome for non-pregnant adults is the proportion of subjects in each group alive, in care and virally suppressed at the routine six-month monitoring visit within 10 months of a positive HIV test or initial HIV care visit if previously diagnosed. The analysis period will start at study enrollment and continue through the earlier of the patient's six-month viral load or 10 months after the patient's HIV test.
10 months after study enrollment
Proportion of pregnant subjects who adhere to ART or the prior PMTCT regimen until delivery
Time Frame: Up to 9 months after study enrollment
The primary outcome for pregnant women is the proportion of subjects in each group who adhere to ART or the prior prevention of mother-to-child transmission (PMTCT) regimen until delivery. The number of weeks a pregnant woman is on ART before delivery is the most important predictor of perinatal HIV transmission7. The guideline change to immediate ART initiation for pregnant women is likely to lead to earlier initiation for most pregnant women, but the intervention will be effective only if patients adhere to ART through the duration of pregnancy. Adherence will be measured as making monthly medication pickups to allow a continuous supply of ARVs through delivery. The analysis period for the primary outcome will start on the day of study enrollment, which is the date of a positive HIV test or the first antenatal visit of the current pregnancy, for women previously diagnosed, and end at the actual or estimated delivery date.
Up to 9 months after study enrollment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Average cost per non-pregnant patient who is alive, in care, and virally suppressed within 10 months of study enrollment
Time Frame: 10 months after study enrollment
10 months after study enrollment
Average cost per pregnant patient who initiates ART within 4 weeks
Time Frame: 3 months after study enrollment
3 months after study enrollment
Proportion virally suppressed at six-month intervals and final date of data censoring
Time Frame: 24 months after enrollment
Proportion of subjects in each track and group alive, on ART, and virally suppressed at six-month intervals and the final date of data censoring
24 months after enrollment
Average time to ART initiation
Time Frame: 24 months after enrollment
24 months after enrollment
Average gestational age at ART initiation and average duration on ART prior to delivery
Time Frame: 3 months after study enrollment
3 months after study enrollment
Patient-level predictors of treatment uptake, retention in care, and viral suppression
Time Frame: 10 months after enrollment
10 months after enrollment
Prevalence of TB symptoms, confirmed TB, time to initiation of TB treatment, and time to initiation of ART among patients with TB
Time Frame: 10 months after enrollment
10 months after enrollment

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Acceptance of rapid initiation strategy
Time Frame: 10 months after enrollment
Acceptance of rapid initiation strategy (% of patients offered rapid initiation who accept)
10 months after enrollment
Time from HIV test to treatment
Time Frame: 10 months after enrollment
Average time elapsed (days) between HIV test and dispensing of first dose of ARVs
10 months after enrollment
Cost to patients
Time Frame: 10 months after enrollment
Average cost to patients of initiating treatment, including travel and other out-of-pocket costs and time spent in clinic
10 months after enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2013

Primary Completion (Actual)

July 1, 2015

Study Completion (Actual)

June 30, 2018

Study Registration Dates

First Submitted

September 7, 2012

First Submitted That Met QC Criteria

October 17, 2012

First Posted (Estimate)

October 19, 2012

Study Record Updates

Last Update Posted (Actual)

January 4, 2019

Last Update Submitted That Met QC Criteria

January 3, 2019

Last Verified

January 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

Data will be made publicly available in the Dryad repository (http://www. datadryad.org/) after the protocol has been closed (anticipated closure December 2018).

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HIV

Clinical Trials on Rapid ART initiation

3
Subscribe